The novel strategies for next-generation cancer treatment: miRNA combined with chemotherapeutic agents for the treatment of cancer

Chiranjib Chakraborty _, Ashish Ranjan Sharma, Garima Sharma, Bimal Kumar Sarkar and Sang-Soo Lee

PDF  |  HTML  |  How to cite

Oncotarget. 2018; 9:10164-10174. https://doi.org/10.18632/oncotarget.24309

Metrics: PDF 2626 views  |   HTML 4375 views  |   ?  


Chiranjib Chakraborty1,2,*, Ashish Ranjan Sharma1,*, Garima Sharma1, Bimal Kumar Sarkar3 and Sang-Soo Lee1

1Institute for Skeletal Aging and Orthopedic Surgery, Hallym University-Chuncheon Sacred Heart Hospital, Chuncheon 24252, Republic of Korea

2Department of Bioinformatics, School of Computer Sciences, Galgotias University, Greater Noida 203201, Uttar Pradesh, India

3Department of Physics, School of Basic and Applied Science, Galgotias University, Greater Noida 203201, Uttar Pradesh, India

*These authors contributed equally to this work

Correspondence to:

Chiranjib Chakraborty, email: [email protected]

Sang-Soo Lee, email: [email protected]

Keywords: miRNA; combination therapy; chemotherapeutic agents; cancer; next-generation therapy

Received: September 13, 2017     Accepted: December 11, 2017     Published: January 23, 2018


Medical practitioners are recommending combination therapy in cancer for its various advantages. Combination therapy increases the efficacy of treatment due to its synergistic effects in cancer treatment. In this post-genomic era, microRNAs (miRNAs) are receiving attention for their role in human disease and disease therapy. In this review, we discuss the combination of miRNAs and chemotherapeutic agents for cancer treatment. Moreover, we attempted to portray the role of miRNAs in cancer therapy; outline combination therapy, especially chemo-combination therapy, and discuss the basis for miRNA-based chemo-combination therapies and chemo-combination therapy with miRNA for cancer treatment.

Creative Commons License All site content, except where otherwise noted, is licensed under a Creative Commons Attribution 4.0 License.
PII: 24309